|
Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries
|
26 July 2017 |
|
Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis
|
14 July 2017 |
|
Novartis CAR-T cell therapy CTL019 unanimously (10-0) recommended for approval by FDA advisory committee to treat pediatric, young adult r/r B-cell ALL
|
12 July 2017 |
|
Novartis Phase III study shows ACZ885 (canakinumab) reduces cardiovascular risk in people who survived a heart attack
|
22 June 2017 |
|
New patient survey highlights need for more action to help severe asthma patients gain control of their disease
|
19 June 2017 |
|
Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting
|
09 June 2017 |
|
Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer
|
02 June 2017 |
|
Novartis receives positive CHMP opinion for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
|
22 May 2017 |
|
Novartis Foundation and partners launch initiative to tackle hypertension and its root causes in low-income urban communities
|
17 May 2017 |
|
Novartis exercises exclusive option agreement with Conatus for the treatment of NASH
|
04 May 2017 |